ATC
CLDX icon

Argent Trust Co’s Celldex Therapeutics CLDX Stock Holding History

Argent Trust Co’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$231K Buy
+6,204
New +$200K 0.01% 724
2026
Q1 		– Sell
-8,481
Closed -$230K – 714
2025
Q4 		$230K Hold
8,481
– – 0.01% 653
2025
Q3 		$219K Buy
+8,481
New +$197K 0.01% 654

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Argent Trust Co's CLDX Position: Q2 2026 in Review

Argent Trust Co opened a new position in Celldex Therapeutics (CLDX) in Q2 2026: 6,204 shares worth $231K. The stake represents 0.01% of the portfolio and ranks #724 among its holdings. This is a return to the name: Argent Trust Co previously reported a position in CLDX as recently as Q4 2025.

Argent Trust Co first reported a position in CLDX in Q3 2025 and has held it in 3 quarters since. 254 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Argent Trust Co held 6,204 shares of Celldex Therapeutics worth $231K as of Q2 2026.
  • Celldex Therapeutics was a new Argent Trust Co position in Q2 2026.
  • Celldex Therapeutics made up 0.01% of Argent Trust Co's portfolio in Q2 2026, its #724 holding.
  • Argent Trust Co first reported a position in Celldex Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 254 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Argent Trust Co's 13F filing for Q2 2026, filed 6 Aug 2026.